NEW YORK (GenomeWeb News) - Gene therapy company Oxford Biomedica said today that it has licensed the rights for RNA interference technology from the University of Massachusetts Medical School and the Carnegie Institute of Washington. 
 
Under the agreement, Oxford Biomedica receives non-exclusive rights under the Carnegie and UMSS licensing programs for the RNAi technology and exclusive rights for the technology’s gene therapy applications using lentiviral vectors.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.